AzTrials
AzTrials

Bladder CancerPhase 2NCT03150836

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

A Phase 2 study testing Durvalumab, Tremelimumab and Radiation Therapy in people with Bladder Cancer, run by Terence Friedlander, MD at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This is a multi-site, randomized, prospective, open-label phase II study. Patients in this study will have localized (cT3-cT4), or metastatic bladder cancer with a symptomatic, intact primary bladder tumor. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Bladder Cancer
What is being tested?
Durvalumab, Tremelimumab and Radiation Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
1 Oct 2017to 1 Sep 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • Locally advanced (cT3 or cT4) or metastatic (N+ or M+) urothelial bladder cancer. Mixed histologies with predominant urothelial pattern are allowed
  • If metastatic disease present patients must have an intact, symptomatic bladder tumor, appropriate for palliative RT to the bladder.
  • Measurable metastatic disease according to RECIST v1.1 criteria. Thus, patients with metastatic disease must have at least 1 lesion, not previously irradiated, that can be accurately measured at baseline as at least 10 mm in the longest diameter (except lymph nodes which must have a short axis greater than or equal to 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurement as per RECIST v1.1 guidelines.
  • Age greater than or equal to 18 years at time of study entry
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Show all 30Show fewer
  • Life expectancy of at least 12 weeks
  • Patients with non-metastatic bladder cancer must be ineligible for cystectomy in the opinion of the treating investigator.
  • Patients must be ineligible for cisplatin-based chemotherapy. The reason for cisplatin ineligibility must be documented. Cisplatin ineligibility is defined as meeting 1 of the following criteria:
  • Creatinine clearance (calculated or measured) less than 60 mL/min
  • Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than or equal to 2 audiometric hearing loss
  • CTCAE Grade 2 or higher peripheral neuropathy
  • New York Heart Association Class III heart failure
  • Any other criteria deemed by the investigator to make the patient unsuitable for cisplatin-based chemotherapy.
  • Subjects must consent to provide an archived tumor specimen from within 12 months prior to study entry (ie, from subject signing consent to participate in the study) for immunologic characterization. If not available, subjects should have at least 1 lesion amenable to biopsy and consent to provide a pre-treatment fresh biopsy. Tumor lesions used for biopsy should not be lesions used as target lesions. Additional archival tissue from beyond 12 months prior to study entry is also requested, if available, to support exploratory analyses.
  • Adequate normal organ and marrow function as defined below:
  • Hemoglobin greater than or equal to 9.0 g/dL
  • Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L (greater than 1500 per mm3)
  • Platelet count greater than or equal to 100 x 109/L (greater than100,000 per mm3)
  • Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN). [This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician].
  • AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be less than or equal to 5x ULN.
  • Serum creatinine CL greater than 30 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance. Serum creatine measurement is the preferred measurement for determining creatinine clearance.
  • Males:
  • Creatinine CL (mL/min) = [Weight (kg) x (140 - Age)] / [72 x serum creatinine (mg/dL)]
  • Females:
  • Creatinine CL (mL/min) = 0.85 x [Weight (kg) x (140 - Age)] / [72 x serum creatinine (mg/dL)]
  • Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: At least 60 years old and no menses for at least 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
  • Women less than 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
  • Women greater than or equal to 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses more than 1 year ago, had chemotherapy-induced menopause with last menses more than 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  • Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visit and examinations and follow-up.

Who cannot join

  • ECOG PS 2 or higher
  • Upper tract-only or urethral-only urothelial cancer
  • Prior cystectomy or definitive RT to the bladder.
  • Prior systemic chemotherapy for bladder cancer
  • History of autoimmune disease, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegner's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
Show all 41Show fewer
  • Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
  • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are not excluded.
  • Patients with controlled type 1 diabetes mellitus on a stable dose of insulin regimen are not excluded.
  • Any chronic skin condition that does not require systemic therapy are not exluded
  • Patients without active autoimmune disease in the last 5 years may be included after consultation with the study physician.
  • Patients with HIV, active hepatitis B (HBV) or active hepatitis C (HCV)
  • Patients with past HBV infection or resolved HBV infection, defined as the presence of hepatitis B core antibody (HBc Ab) and absence of hepatitis B surface antigen (HBsAg) are eligible. HBV DNA must be obtained in these patients prior to day 1 of therapy, but detection of HBV DNA in these patients will not exclude study participation.
  • Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  • Previous IP assignment in the present study
  • Current enrollment/participation in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.
  • Prior exposure to immune-mediated therapy, including but not limited to, durvalumab, tremelimumab, other anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies, and therapeutic anticancer vaccines. Prior BCG or intravestical immune therapy (ie interferon) is not an exclusion to study participation.
  • Prior radiation therapy to the abdomen or pelvis.
  • Any concurrent systemic chemotherapy, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (i.e. hormonal replacement therapy) is acceptable.
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note biopsy and TURBT of the primary tumor is acceptable.
  • History of another primary malignancy except for:
  • Malignancy treated with curative intent and with no known active disease for at least 5 years before the first dose of study drug and of low potential risk for recurrence
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ. (Optional criteria that are dependent on the patient population under investigation.)
  • Patients with incidental finding of early stage prostate cancer will not be eligible.
  • QT interval corrected for heart rate using Fridericia's formula (QTcF) greater than or equal to 470 ms calculated. Any clinically significant abnormalities detected require triplicate ECG results and a mean QT interval corrected for heart rate using Fridericia's formula (QTcF) greater than or equal to 470 ms calculated from 3 ECGs).
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
  • History of primary immunodeficiency
  • History of allogeneic organ transplant
  • History of hypersensitivity to durvalumab, tremelimumab, or any excipient
  • History of hypersensitivity to the combination
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice).
  • History of leptomeningeal carcinomatosis
  • Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
  • Brain metastases or spinal cord compression unless the patient's condition is stable (asymptomatic, no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to the start of study treatment. Following radiotherapy and/or surgery, patients with suspected brain metastases at screening should have an MRI (preferred)/CT, preferably with IV contrast.
  • Subjects with uncontrolled seizures.
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period

Trial locations and contacts

1 site in 1 country.

United States1 site

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94115

Other trials in United States

About this study

Official title: Multi-Institutional Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibition (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Muscle-Invasive or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy

This is a multi-site, randomized, prospective, open-label phase II study. Patients in this study will have localized (cT3-cT4), or metastatic bladder cancer with a symptomatic, intact primary bladder tumor. In this study, patients will undergo stereotactic body radiation therapy (SBRT) to the bladder tumor and will receive durvalumab with or without tremelimumab.

Read the detailed description

The study will commence with a safety lead-in phase at UCSF in which 6 patients are accrued to Regimen A1 (RT + durvalumab). If this is not tolerated then an alternative Regimen A2, containing a lower total radiation dose will accrue 6 patients. If either A1 or A2 is tolerated then patients will be accrued to Regimen B1 (durvalumab, tremelimumab x 2 doses, and RT dose determined from Regimen A) following a 3+3 design for safety. If Regimen B1 is not tolerated an alternative Regimen B2 (durvalumab, tremelimumab x 1 dose, and RT dose determined from regimen A) will accrue following a 3+3 design for safety.

After the safety lead-in for each group is completed, an expansion cohort will accrue patients. In this expansion cohort, patients will be randomized 1:1 to be treated with either regimen A or regimen B dose selected from the safety lead-in stratified by patient population (localized patients and metastatic patients).

Conditions
Bladder Cancer
Being tested
Durvalumab, Tremelimumab, Radiation Therapy
Keywords
bladder cancer, urothelial
Medical subject headings
Urinary Bladder Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DurvalumabDrug

    Also called Imfinzi

    All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.

  • TremelimumabDrug

    Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.

  • Radiation TherapyRadiation

    In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.

Study groups in NCT03150836
Study groupRoleWhat they receive
Safety Lead-In, Regimen A1 Durvalumab + RTExperimentalDurvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
Receives: Drug: Durvalumab; Radiation: Radiation Therapy
Safety Lead-In, Regimen A2 Durvalumab + RTExperimentalIn cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
Receives: Drug: Durvalumab; Radiation: Radiation Therapy
Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RTExperimentalTremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
Receives: Drug: Durvalumab; Drug: Tremelimumab; Radiation: Radiation Therapy
Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RTExperimentalTremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
Receives: Drug: Durvalumab; Drug: Tremelimumab; Radiation: Radiation Therapy
Expansion Cohort, Regimen A: Durvalumab + RTExperimentalDurvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
Receives: Drug: Durvalumab; Radiation: Radiation Therapy
Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RTExperimentalTremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
Receives: Drug: Durvalumab; Drug: Tremelimumab; Radiation: Radiation Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Toxicity according to NCI CTCAE v. 4.03 criteria

    Safety profile

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

  2. Progression-free survival (PFS)

    PFS will be determined from first day of treatment to date of progression. Progression will be defined based on RECIST 1.1

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

Secondary outcomes (7)

  1. Local control at the primary irradiated site

    As determined by RECIST v 1.1 from the date of randomization to the date of first local progression.

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

  2. Pathologic Complete Response (CR) rate of primary irradiated tumor

    As determined by post-treatment biopsy or TURBT in evaluable patients.

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

  3. Overall response rate (ORR)

    The ORR will be as determined by RECIST v 1.1. The ORR will be defined as the number (%) of patients with at least 1 visit response of CR or Partial Response (PR).

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

  4. Abscopal response (in patients with metastatic disease)

    As determined by RECIST v 1.1 with response (PR and CR) sites away from the primary irradiated tumor.

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

  5. Duration of response

    Defined as the time from the date of the first documented response until the first date of documented progression or death.

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

  6. Disease-specific survival

    Defined as the time from the first day of treatment to the date of death related to treatment and/or disease.

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

  7. Overall survival

    Defined as the time from the first day of treatment to the date of death due to any cause.

    Measured: Over the duration of the study, which is estimated to be approximately 50 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 May 2017
  2. Study start1 Oct 2017 (estimated)
  3. Primary completion1 Sep 2021 (estimated)
  4. Study completion1 Sep 2024 (estimated)

Why it stopped: Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03150836
Sponsor's protocol ID
16529
Status last verified
Oct 2017
First submitted
10 May 2017
Last updated
19 Oct 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Durvalumab, Tremelimumab and Radiation Therapy in people with Bladder Cancer, run by Terence Friedlander, MD at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 30 inclusion and 41 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 19 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Toxicity according to NCI CTCAE v. 4.03 criteria (time frame: Over the duration of the study, which is estimated to be approximately 50 months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03150836.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2017; AzTrials last refreshed its copy on 26 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in